Related to PPD to Spin Out Compound-Partnering Segment, Acquire Chinese CRO, and Invest $100M in Celtic Therapeutics

• Merck Serono to Invest More than €150M in R&D Center in China
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Sinovac Expands Vaccine Capabilities with New JV
  
• Meda In-Licenses Commercial Rights to EpiCept’s AML Therapy for $3M
  
• LFB Licenses Thallion’s Early-Stage Candidate for Treating STEC Infections
  
• Cosmo Bio to Distribute Bio-Quant’s Discovery and Preclinical CRO Services in Japan
  
• Beijing Pioneer to Provide Olink’s Duolink Product Line in China
  
• ICON and Tigermed Team Up to Facilitate Access to Chinese Patient Populations
  
• Thermo Fisher Opens New Technology Center in Shanghai
  
• PPD Bolsters Presence in Russia by Opening a New Office
  
• PPD Inks Deal with HIHT University to Increase Network in Northern India
  
• Quintiles Deepens China Commitment with New CRO
  
• Novasep Opens New Facility in Shanghai to Meet East Asia Demand
  
• PPD Plans to Acquire InnoPharm to Augment Its Eastern European Presence
  
• PPD Continues Asia Expansion with Plans for New Facilities in the Philippines and India
  
• Charles River to Take Over Sino-U.S. CRO WuXi in Deal Worth $1.6B
  
• Icon Sets Up Additional Lab Facility in China
  
• GVK and Excel PharmaStudies Join Forces to Help Sponsors Conduct Clinical Trials in India and China
  
• PPD Opens Vaccine Clinical Research Center in Taizhou, China
  
• PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China